Recce Pharmaceuticals Reports Positive Phase I/II Trial Results of RECCE® 327 for the Treatment of Diabetic Foot Infections
Phase I/II trial assessing the safety and efficacy of RECCE® 327 (R327), a broad-spectrum anti-infective as a topical treatment, met...